Edgewise Therapeutics (NASDAQ: EWTX) — Company Overview, News & Financial Data
Edgewise Therapeutics leverages precision medicine to develop therapies for Duchenne and Becker muscular dystrophies.
Edgewise Therapeutics
Edgewise Therapeutics (NASDAQ:EWTX) is a pioneering firm focused on leveraging precision medicine to address a range of serious musculoskeletal diseases with a primary focus on Duchenne and Becker muscular dystrophies. At the heart of its operations, Edgewise Therapeutics is deeply involved in discovering, developing, and deploying transformative therapies designed to improve the lives of individuals grappling with these challenging conditions. Through a robust pipeline of therapeutic candidates, the company aims to halt muscle damage, reduce the severity of symptoms, and ultimately enhance quality of life. With a steadfast commitment to innovation and patient health, Edgewise Therapeutics sets the bar in redefining treatment standards for musculoskeletal diseases, underpinned by rigorous research, strategic collaborations, and a patient-centric approach.
Snapshot
Operations
Products and/or services of Edgewise Therapeutics
- Development of a precision medicine for the treatment of Duchenne Muscular Dystrophy, focusing on preserving muscle function.
- A novel therapeutic approach targeting Becker Muscular Dystrophy to slow disease progression and improve patient quality of life.
- Advancing a pipeline of small molecule therapies aimed at limb-girdle muscular dystrophy, designed to enhance muscle strength.
- Research into targeted treatments for facioscapulohumeral muscular dystrophy, emphasizing muscle protection and function maintenance.
- Creating innovative therapies for the management of myotonic dystrophy, focusing on reducing muscle wasting and improving mobility.
- Development of cutting-edge, non-invasive diagnostics for early detection and monitoring of muscular dystrophies to optimize treatment outcomes.
Edgewise Therapeutics executive team
- Peter A. ThompsonCo-Founder & Independent Chairman
- Kevin KochPresident, CEO & Director
- Badreddin EdrisCo-Founder & Independent Director
- Alan J. RussellCo-Founder, Chief Scientific Officer & Director
- Michael P. NofiChief Financial Officer
- Behrad DerakhshanChief Operating Officer
- Joanne M. DonovanChief Medical Officer
- John R. MooreGeneral Counsel
- Aylin TugcuSenior Vice President of Cardiovascular Clinical Development & Medical Affairs
Latest news about Edgewise Therapeutics
Edgewise sells sevasemten business for $1.55 billion
United StatesEdgewise Therapeutics reports positive Phase 2 heart data
United StatesEdgewise Therapeutics reports functional stabilization in BMD patients
United StatesEdgewise shares data showing EDG-7500 sidesteps heart failure risk in HCM
United States
Key financials
Reported results for Edgewise Therapeutics, in USD.
- Market cap
- 4.1B
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.9
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -191.4M | -167.8M | |
| 0 | -158.8M | -133.8M | |
| 0 | -114.4M | -100.2M | |
| 0 | -22.1M | -15.4M |